#United States #San Diego #Lung Cancer #Genprex #Reqorsa

Genprex to Present Key Findings on Reqorsa® Gene Therapy

Genprex, Inc., a clinical-stage gene therapy company aiming to transform cancer and diabetes treatment, is preparing to unveil significant preclinical data on April 19, 2026, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. This presentation will highlight their lead product, Reqorsa®, or quaratusugene ozeplasmid, which has displayed promising therapeutic potential for lung cancer patients.

Overview of Findings

The data to be presented includes three different research abstracts, each emphasizing the multifaceted role of Reqorsa® in targeting lung cancer, particularly non-small cell lung cancer (NSCLC). CEO Ryan Confer remarked, "The selection of these abstracts signifies robust preclinical evidence supporting the potential of our therapy. Moreover, it's notable that biomarkers for predicting patient response have been identified, which could enhance treatment precision."

The primary points of interest are:

• - Identification of Biomarkers: The studies have identified TROP2 and PTEN as potential biomarkers associated with resistance to Reqorsa® treatment in NSCLC. This discovery is pivotal for optimizing patient selection and improving therapy efficacy.
• - Therapeutic Mechanisms: The mechanisms by which TUSC2, the gene delivered by Reqorsa®, operates against tumor cells are being elucidated further, enhancing the understanding of its function in cancer therapy.

Detailed Study Abstracts

1. TROP2 and PTEN as Biomarkers (Abstract Presentation Number 391)
In this study, researchers established models resistant to TUSC2 gene therapy and identified biomarkers indicative of resistance. The findings revealed that nearly 50% of the NSCLC cell lines tested were resistant to the treatment. Notably, distinct protein expression signatures were discovered, helping pinpoint patients likely to respond positively to the therapy.

2. Quaratusugene ozeplasmid Effectiveness (Abstract Presentation Number 469)
Further examining the effects in both sensitive and resistant models, this study demonstrated that Reqorsa® not only induced apoptosis in sensitive tumors but also in those with acquired resistance. This highlights its potential as an adjunct therapy for patients with advanced NSCLC who face resistance to traditional treatments like alectinib.

3. Enhancing NK Cell Cytotoxicity (Abstract Presentation Number 164)
This critical in vivo research aimed to understand how restoring TUSC2 function influences immune responses. The findings indicate that treatment with Reqorsa® significantly enhances the cytotoxic ability of natural killer (NK) cells against tumors, presenting a dual action of targeting tumor cells directly while boosting the body’s immune response.

Implications for Future Cancer Therapies

The revelations set to be shared at the AACR meeting signify an important leap toward personalized medicine in cancer treatment. By pinpointing biomarkers, Genprex not only aims to solidify the standing of Reqorsa® but also to refine strategies for patient selection, essential for mounting effective therapeutic interventions in clinical settings.

As Genprex prepares for its presentation at AACR 2026, the scientific and medical communities are keenly awaiting findings that could reshape the landscape of available therapies for lung cancer. The upcoming talks promise to enhance understanding not only of how Reqorsa® operates but also of the role of genetic therapies in the fight against challenging cancers, potentially influencing treatment paradigms for future patients worldwide.

About Genprex, Inc.

Founded on the vision of delivering revolutionary therapies, Genprex is committed to addressing the desperate needs of cancer and diabetes patients. By focusing on gene therapy, the company seeks to create innovative treatment avenues for cohorts with limited options. With genuine partnerships and groundbreaking research endeavors, Genprex continues to advance its pipeline towards making a significant impact on the lives of those affected by serious illnesses.